Novartis ties a new round of biosimilar development programs to a partnership deal with India's Biocon
Just a few weeks after Biocon and their partners at Mylan worked out an FDA approval for the first Herceptin biosimilar, the Indian company has …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
